有创脑氧分压引导治疗对创伤性脑损伤患者预后的影响:系统评价与Meta分析
本系统评价与Meta分析检索PubMed、Scopus和Cochrane图书馆,纳入15项比较PbtO2/ICP联合引导治疗与单纯ICP引导治疗的研究,共37,245例TBI患者,其中2,184例接受PbtO2引导治疗。主要终点为3个月和6个月用格拉斯哥结局量表评估的神经功能预后;次要终点包括院内和长期死亡率、颅内高压负担和脑组织缺氧。与ICP引导治疗相比,PbtO2/ICP联合引导治疗与神经功能预后良好概率更高相关(OR 2.21,95%CI 1.72-2.84),与院内生存率更高相关(OR 1.15,95%CI 1.04-1.28)。各分析异质性I²低于40%,但证据质量总体为低至中等。
要点
- 与单纯ICP引导治疗相比,PbtO2/ICP联合引导治疗与TBI患者神经功能预后良好概率更高相关(OR 2.21,95%CI 1.72-2.84)。
- 与单纯ICP引导治疗相比,PbtO2/ICP联合引导治疗与院内生存率更高相关(OR 1.15,95%CI 1.04-1.28)。
- 共纳入15项研究、37,245例TBI患者,其中2,184例接受PbtO2引导治疗。
- 各分析异质性I²低于40%,但证据质量总体为低至中等。
- 作者指出低质量证据强调需要正在进行的III期随机试验的结果。
适用人群与场景
- 创伤性脑损伤(TBI)患者,比较PbtO2/ICP引导治疗与ICP引导治疗的研究人群。
研究设计与关键结果
- 系统评价与Meta分析,检索PubMed、Scopus和Cochrane图书馆,方案注册于PROSPERO,最终纳入15项研究,共37,245例患者,其中2,184例接受PbtO2引导治疗。
- 主要终点:与ICP引导治疗相比,PbtO2/ICP联合引导治疗与神经功能预后良好概率更高相关(OR 2.21,95%CI 1.72-2.84)。
- 次要终点:与ICP引导治疗相比,PbtO2/ICP联合引导治疗与院内生存率更高相关(OR 1.15,95%CI 1.04-1.28)。
- 各分析异质性I²低于40%。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 证据质量总体为低至中等。
- 局限:证据质量低至中等,作者指出需要正在进行的III期随机试验的结果。
对床旁实践的改变
- 作者认为,PbtO2引导治疗与TBI患者死亡率降低和神经功能预后更有利相关。
- 作者指出低质量证据强调需要正在进行的III期随机试验的结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Traumatic brain injury (TBI) is a major public health burden, causing death and disability worldwide. Intracranial hypertension and brain hypoxia are the main mechanisms of secondary brain injury. As such, management strategies guided by intracranial pressure (ICP) and brain oxygen (PbtO2) monitoring could improve the prognosis of these patients. Our objective was to summarize the current evidence regarding the impact of PbtO2-guided therapy on the outcome of patients with TBI. We performed a systematic search of PubMed, Scopus, and the Cochrane library databases, following the protocol registered in PROSPERO. Only studies comparing PbtO2/ICP-guided therapy with ICP-guided therapy were selected. Primary outcome was neurological outcome at 3 and 6 months assessed by using the Glasgow Outcome Scale; secondary outcomes included hospital and long-term mortality, burden of intracranial hypertension, and brain tissue hypoxia. Out of 6254 retrieved studies, 15 studies (n = 37,245 patients, of who 2184 received PbtO2-guided therapy) were included in the final analysis. When compared with ICP-guided therapy, the use of combined PbO2/ICP-guided therapy was associated with a higher probability of favorable neurological outcome (odds ratio 2.21 [95% confidence interval 1.72-2.84]) and of hospital survival (odds ratio 1.15 [95% confidence interval 1.04-1.28]). The heterogeneity (I2) of the studies in each analysis was below 40%. However, the quality of evidence was overall low to moderate. In this meta-analysis, PbtO2-guided therapy was associated with reduced mortality and more favorable neurological outcome in patients with TBI. The low-quality evidence underlines the need for the results from ongoing phase III randomized trials.
参考来源
- Gouvêa Bogossian E, Diosdado A, Barrit S, et al. The Impact of Invasive Brain Oxygen Pressure Guided Therapy on the Outcome of Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Neurocrit Care. 2022. PMID: 36180764. doi:10.1007/s12028-022-01613-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。